Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 10/16/25 → 10/16/27 |
Funding
- Ascentage Pharma Group Inc: $23,062.00
25-LEUK-30 (HQP1351CG301) A GLOBAL MULTICENTER, OPEN LABEL, RANDOMIZED, PHASE 3 REGISTRATIONAL STUDY OF OLVEREMBATINIB (HQP1351) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (POLARIS-2)
- Munker, Reinhold (PI)